Flagship Harbor Advisors’s ARK Genomic Revolution ETF ARKG Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
– Sell
-5,747
Closed -$167K – 814
2025
Q4
$167K Buy
+5,747
New +$172K 0.01% 718
2022
Q3
– Sell
-6,379
Closed -$201K – 588
2022
Q2
$201K Buy
6,379
+160
+3% +$5.59K 0.02% 564
2022
Q1
$286K Buy
+6,219
New +$296K 0.03% 497
2021
Q2
– Sell
-6,182
Closed -$549K – 636
2021
Q1
$549K Buy
6,182
+436
+8% +$43.2K 0.06% 321
2020
Q4
$536K Buy
5,746
+567
+11% +$45.2K 0.07% 289
2020
Q3
$330K Buy
5,179
+1,359
+36% +$79.6K 0.04% 341
2020
Q2
$199K Buy
3,820
+1,111
+41% +$47.7K 0.03% 461
2020
Q1
$85K Sell
2,709
-174
-6% -$5.81K 0.02% 594
2019
Q4
$97K Buy
2,883
+12
+0.4% +$381 0.02% 615
2019
Q3
$84K Sell
2,871
-200
-7% -$6.5K 0.02% 633
2019
Q2
$105K Buy
3,071
+100
+3% +$3.21K 0.02% 553
2019
Q1
$97K Buy
2,971
+471
+19% +$13.9K 0.02% 569
2018
Q4
$59K Buy
2,500
+2,100
+525% +$59.2K 0.01% 653
2018
Q3
$13K Buy
+400
New +$12.7K ﹤0.01% 1284

Other funds holding ARKG

Flagship Harbor Advisors's ARKG Position: Q1 2026 in Review

Flagship Harbor Advisors sold out of ARK Genomic Revolution ETF (ARKG) in Q1 2026, closing a stake of 5,747 shares — an estimated $167K sold.

Flagship Harbor Advisors first reported a position in ARKG in Q3 2018 and held it in 14 quarters. The position peaked at $549K in Q1 2021. 220 funds tracked by Wall St. Rank hold ARKG as of Q1 2026.

  • Flagship Harbor Advisors reported no remaining ARK Genomic Revolution ETF position as of Q1 2026 after selling out during the quarter.
  • Flagship Harbor Advisors sold 5,747 ARK Genomic Revolution ETF shares in Q1 2026, an estimated $167K.
  • Flagship Harbor Advisors first reported a position in ARK Genomic Revolution ETF in Q3 2018 and held it in 14 quarters.
  • Flagship Harbor Advisors's ARK Genomic Revolution ETF position peaked at $549K in Q1 2021.
  • 220 funds tracked by Wall St. Rank held ARK Genomic Revolution ETF as of Q1 2026.

Based on Flagship Harbor Advisors's 13F filing for Q1 2026, filed 28 Apr 2026.